ADGRD1 and glioblastoma: Alternatively, given the de novo expression of GPR133 in GBM relative to healthy nonneoplastic brain tissue, anti-GPR133 internalizing antibodies could be used to deliver antibody-drug conjugates to GBM cells (21, 29, 35).